These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24730084)

  • 1. CYP2D6 pharmacogenomics of tamoxifen treatment.
    ; ;
    Technol Eval Cent Assess Program Exec Summ; 2014 Jan; 28(8):1-4. PubMed ID: 24730084
    [No Abstract]   [Full Text] [Related]  

  • 2. CYP2D6 pharmacogenomics of tamoxifen treatment.
    Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
    [No Abstract]   [Full Text] [Related]  

  • 3. The ethics of CYP2D6 testing for patients considering tamoxifen.
    Hartman AR; Helft P
    Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 genotyping and the pharmacogenetics of tamoxifen.
    Flockhart D
    Clin Adv Hematol Oncol; 2008 Jul; 6(7):493-4. PubMed ID: 18654115
    [No Abstract]   [Full Text] [Related]  

  • 5. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
    Margolin S; Lindh JD; Thorén L; Xie H; Koukel L; Dahl ML; Eliasson E
    Pharmacogenomics; 2013 Apr; 14(6):613-22. PubMed ID: 23570465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
    Damkier P
    Pharmacogenomics; 2017 Jun; 18(8):753-754. PubMed ID: 28592184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 genotype and tamoxifen response.
    Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
    Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
    [No Abstract]   [Full Text] [Related]  

  • 8. Interpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics Consortium.
    Province MA; Altman RB; Klein TE
    Clin Pharmacol Ther; 2014 Aug; 96(2):144-6. PubMed ID: 25056393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should CYP2D6 be genotyped when treating with tamoxifen?
    Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
    Pharmacogenomics; 2017 Jun; 18(8):755-756. PubMed ID: 28593824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.
    Skaar TC; Desta Z
    Clin Pharmacol Ther; 2018 May; 103(5):755-757. PubMed ID: 29473149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should CYP2D6 be genotyped when treating with tamoxifen?
    Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
    Pharmacogenomics; 2016 Dec; 17(18):1967-1969. PubMed ID: 27883289
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenomics of tamoxifen and irinotecan therapies.
    Algeciras-Schimnich A; O'Kane DJ; Snozek CL
    Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
    Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
    Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response.
    Wegman PP; Wingren S
    Breast Cancer Res; 2005 Mar; 7(6):E7. PubMed ID: 16280043
    [No Abstract]   [Full Text] [Related]  

  • 18. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
    Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
    Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
    Woods B; Veenstra D; Hawkins N
    Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.